O	0	4	Does
B-intervention	5	17	preoperative
I-intervention	18	22	core
I-intervention	23	29	needle
I-intervention	30	36	biopsy
O	37	45	increase
O	46	54	surgical
O	55	59	site
O	60	70	infections
O	71	73	in
O	74	80	breast
O	81	87	cancer
O	88	95	surgery
O	95	96	?

O	97	107	Randomized
O	108	113	study
O	114	116	of
O	117	127	antibiotic
O	128	139	prophylaxis
O	139	140	.

O	141	153	Preoperative
O	154	158	core
O	159	165	needle
O	166	174	biopsies
O	175	178	may
O	179	187	increase
O	188	191	the
O	192	196	risk
O	197	199	of
O	200	208	surgical
O	209	213	site
O	214	223	infection
O	224	225	(
O	225	228	SSI
O	228	229	)
O	230	232	in
O	233	239	breast
O	240	246	cancer
O	247	254	surgery
O	254	255	.

O	256	259	The
O	260	267	purpose
O	268	270	of
O	271	275	this
O	276	286	randomized
O	287	292	trial
O	293	296	was
O	297	299	to
O	300	309	determine
O	310	317	whether
O	318	319	a
O	320	332	prophylactic
O	333	343	antibiotic
O	344	349	would
O	350	357	prevent
O	358	361	SSI
O	362	367	under
O	368	373	these
O	374	384	conditions
O	384	385	.

O	386	393	Imaging
O	393	394	-
O	394	400	guided
O	401	409	multiple
O	410	414	core
O	415	421	needle
O	422	430	biopsies
O	431	435	were
O	436	445	performed
O	446	449	one
O	450	452	to
O	453	456	two
O	457	462	weeks
O	463	468	prior
O	469	471	to
O	472	479	surgery
O	480	482	to
O	483	489	obtain
O	490	502	confirmation
O	503	505	of
O	506	509	the
O	510	518	presence
O	519	521	of
O	522	528	breast
O	529	535	cancer
O	535	536	.

O	537	541	Then
O	542	545	the
O	546	554	patients
O	555	559	were
O	560	570	randomized
O	571	573	to
O	574	581	receive
O	582	588	either
O	589	590	a
O	591	597	single
O	598	609	intravenous
O	610	614	dose
O	615	617	of
O	618	619	1
O	619	620	.
O	620	621	0
O	622	623	g
O	624	626	of
O	627	640	dicloxacillin
O	641	642	(
O	642	643	n
O	644	645	=
B-intervention-participants	646	649	144
O	649	650	)
O	651	653	or
B-control	654	661	placebo
I-control	662	670	infusion
I-control	671	673	of
I-control	674	680	saline
O	681	682	(
O	682	683	n
O	684	685	=
B-control-participants	686	689	148
O	689	690	)
O	691	693	30
O	694	697	min
O	698	703	prior
O	704	706	to
O	707	716	operation
O	716	717	.

O	718	723	After
O	724	730	breast
O	731	738	surgery
O	738	739	,
O	740	750	incisional
O	751	760	morbidity
O	761	764	was
O	765	774	monitored
O	775	778	for
O	779	781	30
O	782	786	days
O	786	787	.

O	788	791	The
O	792	798	number
O	799	801	of
O	802	806	SSIs
O	807	810	was
O	811	819	compared
O	820	824	with
O	825	829	that
O	830	832	in
O	833	836	672
O	837	845	patients
O	846	853	treated
O	854	860	before
O	861	864	the
O	865	879	implementation
O	880	882	of
O	883	887	core
O	888	894	needle
O	895	903	biopsies
O	903	904	.

O	905	908	The
O	909	916	patient
O	917	932	characteristics
O	933	936	and
O	937	941	risk
O	942	949	factors
O	950	953	for
O	954	957	SSI
O	958	962	were
O	963	970	similar
O	971	973	in
O	974	977	the
O	978	988	antibiotic
O	989	1000	prophylaxis
O	1001	1004	and
O	1005	1012	placebo
O	1013	1019	groups
O	1019	1020	.

O	1021	1024	The
B-outcome	1025	1034	incidence
I-outcome	1035	1037	of
I-outcome	1038	1041	SSI
O	1042	1045	was
O	1046	1047	7
O	1047	1048	.
O	1048	1049	2
O	1049	1050	%
O	1051	1052	(
O	1052	1054	21
O	1054	1055	/
O	1055	1058	292
O	1058	1059	)
O	1060	1062	in
O	1063	1066	the
O	1067	1078	prospective
O	1079	1084	trial
O	1085	1093	compared
O	1094	1098	with
O	1099	1100	6
O	1100	1101	.
O	1101	1102	8
O	1102	1103	%
O	1104	1105	(
O	1105	1107	46
O	1107	1108	/
O	1108	1111	672
O	1111	1112	)
O	1113	1115	in
O	1116	1119	the
O	1120	1133	retrospective
O	1134	1140	cohort
O	1141	1142	(
O	1142	1143	p
O	1144	1145	=
O	1146	1147	0
O	1147	1148	.
O	1148	1151	890
O	1151	1152	)
O	1152	1153	.

O	1154	1157	The
B-outcome	1158	1167	incidence
I-outcome	1168	1170	of
I-outcome	1171	1184	postoperative
I-outcome	1185	1189	SSIs
O	1190	1193	was
B-iv-bin-percent	1194	1195	5
I-iv-bin-percent	1195	1196	.
I-iv-bin-percent	1196	1197	6
I-iv-bin-percent	1197	1198	%
O	1199	1200	(
B-iv-bin-abs	1200	1201	8
O	1201	1202	/
B-intervention-participants	1202	1205	144
O	1205	1206	)
O	1207	1209	in
O	1210	1213	the
O	1214	1227	dicloxacillin
O	1228	1233	group
O	1234	1237	and
B-cv-bin-percent	1238	1239	8
I-cv-bin-percent	1239	1240	.
I-cv-bin-percent	1240	1241	8
I-cv-bin-percent	1241	1242	%
O	1243	1244	(
B-cv-bin-abs	1244	1246	13
O	1246	1247	/
B-control-participants	1247	1250	148
O	1250	1251	)
O	1252	1254	in
O	1255	1258	the
O	1259	1266	placebo
O	1267	1272	group
O	1273	1274	(
O	1274	1275	p
O	1276	1277	=
O	1278	1279	0
O	1279	1280	.
O	1280	1283	371
O	1283	1284	)
O	1284	1285	.

O	1286	1289	For
O	1290	1293	the
O	1294	1299	first
O	1300	1303	two
O	1304	1309	weeks
O	1309	1310	,
O	1311	1316	there
O	1317	1320	was
O	1321	1322	a
O	1323	1326	non
O	1326	1327	-
O	1327	1338	significant
O	1339	1344	trend
O	1345	1347	to
O	1348	1353	fewer
B-outcome	1354	1358	SSIs
O	1359	1361	in
O	1362	1365	the
O	1366	1376	antibiotic
O	1377	1382	group
O	1383	1384	(
O	1384	1385	n
O	1386	1387	=
B-iv-bin-abs	1388	1389	1
O	1389	1390	)
O	1391	1395	than
O	1396	1399	the
O	1400	1407	placebo
O	1408	1413	group
O	1414	1415	(
O	1415	1416	n
O	1417	1418	=
B-cv-bin-abs	1419	1420	4
O	1420	1421	)
O	1421	1422	.

B-outcome	1423	1427	Body
I-outcome	1428	1432	mass
I-outcome	1433	1438	index
I-outcome	1438	1439	,
I-outcome	1440	1447	smoking
I-outcome	1447	1448	,
I-outcome	1449	1451	or
I-outcome	1452	1460	previous
I-outcome	1461	1468	illness
O	1469	1472	did
O	1473	1476	not
O	1477	1483	affect
O	1484	1487	the
O	1488	1498	likelihood
O	1499	1501	of
O	1502	1505	SSI
O	1505	1506	.

O	1507	1511	Core
O	1512	1518	needle
O	1519	1525	biopsy
O	1526	1529	did
O	1530	1533	not
O	1534	1542	increase
O	1543	1546	the
B-outcome	1547	1556	incidence
I-outcome	1557	1559	of
I-outcome	1560	1563	SSI
O	1563	1564	.

O	1565	1575	Antibiotic
O	1576	1587	prophylaxis
O	1588	1591	did
O	1592	1595	not
O	1596	1603	prevent
O	1604	1607	SSI
O	1607	1608	,
O	1609	1617	probably
O	1618	1625	because
O	1626	1628	so
O	1629	1632	few
O	1633	1643	infections
O	1644	1652	occurred
O	1652	1653	.
